What does the research say about freeze-thaw cycles?
Freeze-thaw cycling is a laboratory processing step used to disrupt cells and preserve extracellular matrix architecture. This page summarises the research literature on its use in scaffold preparation and cell-handling
In the research literature, a freeze-thaw cycle is a repeated sequence of freezing a biological sample and then thawing it, typically used as a physical disruption step in tissue processing or as a preservation and handling step in cell workflows. It is not a compound and has no sequence, formula or molecular weight; it is a process variable. In the studies summarised here it appears in two distinct roles: as part of decellularisation protocols that strip cells from a tissue while attempting to preserve the extracellular matrix (ECM), and as a handling constraint that investigators design around when live cells are part of a delivery system.
The work described below centres on extracellular matrix scaffolds and mesenchymal stem cell biology, with the surrounding literature touching on fibroblast function and localised delivery systems.
Research Studies
Freeze-thaw cycles and decellularized tendon scaffold preparation in a rat model
In a study of tendon repair, decellularized tendon scaffold (DTS) was prepared from rat Achilles tendons using freeze-thaw cycles followed by sodium dodecyl sulfate decellularization, with the stated aim of preserving ECM structure [1]. The scaffold was then seeded with adipose-derived mesenchymal stem cells (AD-MSCs) and combined with G-CSF injection in a rat model of tendon injury [1]. The authors framed the approach as integrating three elements — MSCs, a tissue-specific ECM scaffold, and a bioactive factor — on the rationale that tendon injuries heal poorly and recur, creating a clinical burden [1].
In vitro work in the same study assessed AD-MSC viability, tenogenic gene expression, and scratch wound closure [1]. The in vivo component was conducted in rats [1].
Freeze-thaw cycles and the preservation of ECM architecture
The rationale for using freeze-thaw cycling in the DTS protocol was structural: the method was described as preserving ECM structure through the decellularisation process [1]. This places freeze-thaw cycling in the category of processing steps whose value is judged by what remains of the matrix after cells are removed, rather than by any direct biological activity of the cycling itself.
| Parameter | Detail reported |
|---|---|
| Tissue source | Rat Achilles tendon [1] |
| Decellularisation | Freeze-thaw cycles plus sodium dodecyl sulfate [1] |
| Scaffold designation | Decellularized tendon scaffold (DTS) [1] |
| Cells seeded | Adipose-derived MSCs (AD-MSCs) [1] |
| Additional factor | G-CSF injection [1] |
| Model | Rat [1] |
Freeze-thaw cycles and AD-MSC viability and tenogenic gene expression
AD-MSC viability, tenogenic gene expression, and scratch wound closure were assessed in vitro as part of the tendon repair study [1]. These readouts address whether cells seeded onto a scaffold prepared with freeze-thaw cycling remain viable and adopt markers associated with tendon-lineage activity. The evidence block does not report the numerical results of these assays, so no values are given here.
Freeze-thaw cycles and scratch wound closure assays
Scratch wound closure was one of the in vitro measures used alongside viability and tenogenic gene expression in the AD-MSC/DTS work [1]. This is a cell-migration readout conducted in culture, not a wound-healing outcome in a living organism.
Freeze-thaw cycles and tendon repair outcomes in rats
The tendon repair study was conducted in a rat model, and the combination of DTS, AD-MSCs, and G-CSF injection was investigated for its effect on tendon repair in that model [1]. Any finding from this work is a finding in rats. It does not establish an effect in humans, and the evidence block does not provide human data.
Freeze-thaw cycles and cryogenic handling constraints in live-cell delivery
A separate line of work on diabetic wound repair describes a non-cryogenic dugout-structured microneedle patch for co-delivery of irisin and fibroblasts [2]. That report notes that diabetic wounds are difficult to treat because of persistent inflammation and impaired fibroblast function, and that while microneedle systems offer a minimally invasive route for localised delivery, live-cell applications have been constrained by dehydration damage and cryogenic handling requirements [2]. Freeze-thaw cycling sits within that constraint category: it is a handling requirement that delivery-system designers may seek to avoid when the payload is living cells [2].
Freeze-thaw cycles and the distinction between process and payload
Across the evidence summarised here, freeze-thaw cycling functions as a process step or a handling constraint rather than as an active agent. In the tendon work it is part of scaffold preparation [1]; in the microneedle work, cryogenic handling is named as a limitation that non-cryogenic designs aim to circumvent [2].
Freeze-thaw cycles and the limits of the current evidence
The tendon repair findings come from a rat model and from in vitro assays [1]. The microneedle report concerns a delivery-system design problem in the context of diabetic wounds [2]. Neither source provides human outcome data, and the evidence block does not supply comparative freeze-thaw protocol parameters, cycle counts, or temperatures. Claims about optimal cycling conditions are therefore not supported here and are not made.
If you are reading this for personal health reasons
The materials discussed on this page are supplied for laboratory research use only, and we do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing here should be read as a statement about safety or effect in humans.
Sources
- [1] Decellularized tendon scaffold seeded with adipose-derived MSCs and supplemented with G-CSF injection promotes tendon repair in a rat model. https://pubmed.ncbi.nlm.nih.gov/42531629/
- [2] A Non-Cryogenic Dugout-Structured Microneedle Patch for Co-Delivery of Irisin and Fibroblasts in Diabetic Wound Repair. https://pubmed.ncbi.nlm.nih.gov/42608773/